Evaluation of Safety and Efficacy of the Accero® (Heal) Stent for Intracranial Aneurysm Treatment
Launched by ACANDIS GMBH · May 17, 2019
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the safety and effectiveness of a device called the Accero® (Heal) Stent, which is used to treat intracranial aneurysms—bulges in blood vessels in the brain that can be dangerous. The goal of the study is to confirm that using this stent is safe for patients who need this type of treatment.
Anyone interested in participating must be treated with the Accero® (Heal) Stent following the manufacturer's instructions. However, people with certain conditions, such as a modified Rankin Scale score greater than 2 (which measures disability) or a Hunt and Hess score greater than 3 (which assesses the severity of a type of bleeding in the brain), will not be eligible. If you join this trial, you can expect close monitoring and care throughout the process to ensure your safety. The trial is currently recruiting participants of all ages and genders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Any patient treated with ACCERO® (heal) Stent according to IFU and has signed the informed consent
- Exclusion Criteria:
- • - Patient is participating in another clinical trial
About Acandis Gmbh
Acandis GmbH is a leading medical technology company specializing in the development and commercialization of innovative solutions for interventional neuroradiology and vascular surgery. With a commitment to enhancing patient outcomes, Acandis focuses on designing advanced devices that address complex vascular conditions. The company leverages cutting-edge research and development to create products that prioritize safety and efficacy, while also providing comprehensive support to healthcare professionals. Dedicated to clinical excellence, Acandis actively participates in clinical trials to validate the performance of its solutions and to advance the field of minimally invasive therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Magdeburg, , Germany
Recklinghausen, , Germany
Berlin, , Germany
Düsseldorf, , Germany
Hamburg, , Germany
Meppen, , Germany
Patients applied
Trial Officials
Maxim Bester, PD. Dr.
Principal Investigator
Universitätsklinikum Hamburg-Eppendorf
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials